Drugsupdate.com is up for sale. To own one of the most recognized online brands by doctors in India with millions of visitors - click here.
For the treatment of metastatic melanoma by Bristol-Myers Squibb; Approved March 201
Yervoy (ipilimumab) is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a molecule on T cells that suppresses the immune response. Blockade of CTLA-4 augments T-cell activation and proliferation and ipilimumab works via T-cell mediated anti-tumor immune responses.
Yervoy is specifically indicated for the treatment of unrespectable or metastatic melanoma.
Yervoy is supplied as a solution for intravenous administration. The recommended dose of Yervoy is 3 mg/kg administered intravenously over 90 minutes every three weeks for a total of four doses.
Adverse events associated with the use of Yervoy may include, but are not limited to, the following:
Mechanism of Action
Yervoy (ipilimumab) is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a molecule on T cells that suppresses the immune response. CTLA-4 is a negative regulator of T-cell activation. Ipilimumab binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation. The mechanism of action of ipilimumab’s effect in patients with melanoma is indirect, possibly through T-cell mediated anti-tumor immune responses.